Market Research Outlook on Dyslipidemia - Pipeline Review, H1 2017

Dyslipidemia - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Complete report available @ Dyslipidemia - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 17, 19, 14, 4, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Acasti Pharma Inc Akcea Therapeutics Inc Allergan Plc Amgen Inc Arisaph Pharmaceuticals Inc AstraZeneca Plc BASF SE BCWorld Pharm Co Ltd BioRestorative Therapies Inc Boryung Pharmaceutical Co Ltd Cadila Pharmaceuticals Ltd Cardax Inc Catabasis Pharmaceuticals Inc Celon Pharma SA Cerenis Therapeutics Holding SA Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp Connexios Life Sciences Pvt Ltd CymaBay Therapeutics Inc Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd Eli Lilly and Company Esperion Therapeutics Inc Gemphire Therapeutics Inc Gilead Sciences Inc GlaxoSmithKline Plc Golden Biotechnology Corp HanAll Biopharma Co Ltd Hanmi Pharmaceuticals Co Ltd Huons Co Ltd Hyundai Pharmaceutical Co Ltd Innovent Biologics Inc IPCA Laboratories Ltd Jeil Pharmaceutical Co Ltd Jenrin Discovery Inc JW Pharmaceutical Corp Kissei Pharmaceutical Co Ltd Kotobuki Pharmaceutical Co Ltd Kowa Company Ltd Kuhnil Pharmaceutical Co Ltd Kyorin Pharmaceutical Co Ltd Lipicard Technologies Ltd Lipigon Pharmaceuticals AB LipimetiX Development Inc Lotus Pharmaceutical Co Ltd Matinas BioPharma Holdings Inc Merck & Co Inc Nippon Chemiphar Co Ltd Omeros Corp Pfizer Inc Pharmena SA Protalix BioTherapeutics Inc Regeneron Pharmaceuticals Inc Samjin Pharmaceutical Co Ltd Sancilio & Company Inc Takeda Pharmaceutical Company Ltd Tasly Pharmaceutical Group Co Ltd Torrent Pharmaceuticals Ltd Yuhan Corp Zydus Cadila Healthcare Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###